Jain Global’s Sarepta Therapeutics SRPT Stock Holding History

Jain Global’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-87,428	Closed	-$1.9M	–	2026
2026 Q1	$1.9M	Buy	+87,428	New	+$1.69M	0.01%	695
2025 Q3	–	Sell	-282,437	Closed	-$4.83M	–	1465
2025 Q2	$4.83M	Buy	+282,437	New	+$12M	0.04%	348
2025 Q1	–	Sell	-18,193	Closed	-$2.21M	–	1327
2024 Q4	$2.21M	Buy	+18,193	New	+$2.23M	0.07%	223

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Jain Global's SRPT Position: Q2 2026 in Review

Jain Global sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 87,428 shares — an estimated $1.9M sold.

Jain Global first reported a position in SRPT in Q4 2024 and held it in 3 quarters. The position peaked at $4.83M in Q2 2025. 324 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Jain Global reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
Jain Global sold 87,428 Sarepta Therapeutics shares in Q2 2026, an estimated $1.9M.
Jain Global first reported a position in Sarepta Therapeutics in Q4 2024 and held it in 3 quarters.
Jain Global's Sarepta Therapeutics position peaked at $4.83M in Q2 2025.
324 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Jain Global's 13F filing for Q2 2026, filed 14 Aug 2026.